Chapter 14 - The Second Generation Program
Second Generation Study was not an official title.
It appeared in Dr. Hale’s private research notes.
The idea began five years earlier.
Northshore possessed thousands of archived wellness samples from employees and former employees.
Most were collected under broad consent language permitting deidentified research.
Hale saw commercial opportunity.
If biomarker patterns appeared heritable, children could provide longitudinal validation.
That concept alone was not inherently unethical.
Research on inherited traits exists.
The problem was how they pursued it.
No clear reconsent from former employees.
No transparent pediatric protocol.
No independent ethics process investigators could locate.
Recruitment through household benefits.
Guardians paid separately.
Language softened.
Implants hidden behind wellness procedures.
Children became “second generation feasibility subjects.”
Jennifer’s JT 03 profile was one of dozens selected.
Leo was not the only descendant.
Eleven of the twelve pediatric candidates linked to prior employee wellness data.
The twelfth was a control.
The selection process had been planned.
That meant Greg was not the origin.
He was the person Northshore found easiest to recruit.
Why?
Debt.
Employee status.
Household access.
Weak guardian verification.
He fit their operational needs.
Hale’s notes:
N09 caregiver highly motivated by compensation.
Retention probability high.
The company had assessed Greg’s financial motivation.
A recruiter wrote:
Household debt load suggests stipend meaningful.
Jennifer read that and went silent.
“They chose someone desperate.”
Maybe.
At least they noticed desperation and viewed it as retention strength instead of coercion risk.
That was ethically damning even before courts decided anything.
Another note:
Maternal guardian may be more cautious due prior employment familiarity. Route through current employee.
They deliberately avoided Jennifer.
Because she might ask better questions.
That was the most personal corporate decision.
Greg was not simply convenient.
Jennifer was intentionally bypassed.
Northshore CEO Martin Shaw said he had never seen the note.
Kara had.
Dana had.
Hale wrote it.
The investigative line became clearer.
Then Redwood Medical withdrew entirely from acquisition discussions.
Not because liability had been adjudicated.
Because unresolved pediatric research risk made the deal impossible to value.
Northshore’s planned purchase of NerveLine also collapsed.
Employees panicked.
Shareholders demanded answers.
Leo knew none of that.
Good.
He was nine.
His days returned to school, therapy, video games, and arguing about vegetables.
Jennifer sold Greg’s truck only after legal ownership was clarified during separation.
Not revenge.
Debt management.
She reduced household expenses.
The secret study money remained frozen pending financial proceedings because some might be marital income, some contract compensation, some subject to claims.
Messy.
Normal law.
Greg’s criminal case moved slowly.
He faced serious allegations connected to child abuse, unlawful restraint, and fraudulent medical authorization.
No final outcome yet.
Dr. Hale and company officials faced regulatory and potential legal scrutiny.
Again, unresolved.
Thomas testified only about what he personally observed.
Greg dragging Leo.
The wrist mark.
The fever.
The swelling.
The foreign body.
The attempt to leave.
He did not become an expert on corporate intent.
That discipline strengthened the case.
Sarah testified too.
Her memory of Greg’s first sentence remained exact.
“He’s not worth missing a shift over.”
Then Thomas learned something uncomfortable.
His own hospital had once accepted a grant from Northshore.
Two years earlier.
For emergency department wearable sensor testing.
Adults.
No implants.
Nothing improper found.
Still, the name had entered Bayhaven before Leo.
Administration reviewed the grant.
Independent auditors found no connection to the pediatric program.
Thomas felt relief.
Then shame for feeling relief.
Sarah understood.
“You wanted the line to stop somewhere.”
“Yes.”
“It can.”
Not every institution had to be secretly involved.
That mattered too.
Then Jennifer received a letter from Northshore.
Formal notice that archived JT 03 samples would be destroyed upon her request pending regulatory retention requirements.
She stared at it.
“Do I want that?”
Her attorney said:
“You do not have to decide today.”
For once, nobody pushed speed.
She chose to preserve them temporarily because they might be evidence.
Her biological data had been used without proper new consent.
Now she decided what happened next.
Small reversal.
Large meaning.
Then Leo brought home a drawing.
A gray room.
A green light.
A red light.
A man holding the reader.
In the corner, another child.
Jennifer stared.
“Who is that?”
Leo shrugged.
“Boy from the clinic.”
“You saw another kid?”
“Yes.”
“When?”
“The first day.”
“Did you know his name?”
“No.”
Leo pointed to something on the drawing.
The other boy had a bandage near his ear.
Not arm.
Not cheek.
Behind the ear.
Jennifer called Bell.
The official pediatric subject list contained only twelve numbers.
None matched the date Leo remembered.
The clinic appointment log showed an additional child.
No study number.
No consent file.
No reported subject.
May you like
Someone had participated completely off the books.
Continue to the next part: The officially documented pediatric study may not include every child who received a device.
